If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:Biotechs Are Back In Favor Thanks to Positive Developments. A Forbes article on Monday noted how Biotech is back in favor thanks to a "number of new drug approvals, affirmative data, and accelerated sales and earnings growth at the big biotech companies." The article went on to note that those trends along with a robust M&A environment are the key ingredients for a sustainable biotech bull market rally which has already helped to drive up the price of many biotech stocks. What's Behind The Booming Biotech IPO Market. Another Forbes article from last weekend noted that after a decade long drought, there have been over 30 new biotech offerings this year and more than $2.5 billion raised for the best IPO market since 2000 and the second busiest IPO year in the 30+ year history of biotech. The article then went into some detail about the following key trends helping the biotech market: 1) Generalists are back, chasing the sector's outperformance; 2) Recent IPO vintages have done very well in biotech; 3) Biotech is benefiting from a 'recycling-scarcity' cycle; and 4) The JOBS Act has certainly greased the skids of the offering process with its test-the-water and confidential S1 approach. Four Upcoming Biotech IPOs. FierceBiotech.com noted this week's IPOs on Monday, which are Ophthotech Corp, Foundation Medicine Inc, Evoke Pharma and Fate Therapeutics Inc. Expect biotech investors and analysts alike to be watching how these IPOs perform and then how their shares perform in the coming days, weeks and months. BIND Therapeutics IPOs raises $70.5 million. Last Friday, small cap BIND Therapeutics, which has no products on the market (BIND-014 is its most advanced treatment candidate as its in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer), fell 6.1% to $14.09 on its first day of trading. The BIND Therapeutics IPO raised $70.5 million. Cell Therapeutics Raises $15 Million. Late last week, small cap Cell Therapeutics, a small cap biopharmaceutical company with integrated portfolio of oncology products aimed at cancer, announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC for gross proceeds of approximately $15 million (net proceeds of $14.8 million). All of the shares of Series 18 Preferred Stock were converted and investors received 15,000,000 shares of common stock issuable upon conversion. The 2013 Fierce 15 Biotech. FierceBiotech.com has also come out with its annual Fierce 15 report detailing fifteen up-and-coming private biotechs who naturally could end up as the next hot IPO. So it might be worthwhile to browse through the list for future investment ideas. TNI BioTech Makes Important Announcements. Up and coming small cap TNI BioTech was formed in 2012 to acquire patents, develop treatments, market and license immunotherapies for the treatment of cancer, HIV/AIDS and autoimmune diseases using methionine enkephalin (MENK) and low dose naltrexone (LDN) with its first patents and therapies being acquired from Dr. Nicholas P. Plotnikoff and Dr. Fengping Shan. TNI BioTech recently announced a manufacturing and supply agreement with Laboratorios Ramos for the production of Low Dose Naltrexone ("LDN"), which can normalize the immune system and help those suffering from HIV/AIDS, cancer, autoimmune diseases and central nervous system disorders, for commercial use. In addition, TNI BioTech has given a financing update which noted the company has received $826,250 as consideration for the exercise of the previously-issued warrants and $531,250 for the purchase of common stock under the Private Placement, for an aggregate sum of $1,357,500.